The Board of Directors at CellaVision has appointed Simon Østergaard as Chief Executive Officer. Simon Østergaard takes on his new role in March 2021, succeeding Zlatko Rihter, who left the company on November 28. Until the date of entry, Magnus Blixt continues in his role as acting CEO and then returns to his regular role as CFO. Simon Østergaard has extensive international experience from the medical device and diagnostic (IVD) industries while holding various leadership positions covering the entire value chain from business development, research & development, quality assurance, operations to sales and marketing. Simon Østergaard joins CellaVision from Agilent Technologies where he holds the role as Vice President & General Manager for the global Pathology Division and the role as Country General Manager for Denmark. In Simon Østergaard's most recent assignment as Vice President & General Manager of the Pathology Division at Agilent Technologies, Simon Østergaard is leading its global franchise for cancer diagnostics with employees located in Copenhagen, Santa Clara, Carpinteria and Penang in addition to the global sales footprint.
CellaVision AB is a Sweden-based company active in the medical technology sector. The Company develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision ABâs product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The Company operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.